Zurich (AWP) – The Swiss Stock Exchange ended on a negative note on Friday. Investors are still awaiting a trade agreement between the European Union (EU) and the United States. The business results season continued, with the data from the SGS inspection and certification giant in terms of Blue Chips.
In New York, Wall Street advanced in the morning, welcoming a new volley of results and remaining in the expectation of a trade agreement between the European Union and the United States.
The SMI ended down 0.75% to 11,955.73 points, with a lower at 11,918.01 and a higher at 12,030.49. The SLI sold 0.59% to 1994.12 points and the SPI lost 0.68% to 16,711.90 points. Of the 31 star values, 21 fell and ten advanced.
Adecco (+2.9%) finished on the highest step of the podium, ahead of Sika (+1.1%) and Amrize (+0.5%).
Chocolate medal, the Geneva specialist in SGS inspection and certification (+0.4%) saw his income and profitability improve in the first half. Management expects growth to accelerate growth for the coming months.
On the losers side, the red lantern of the day returns to the Bon Lindt (-2.6%), behind Roche (-2.2%) and Givaudan (-2.0%).
The Committee for Human Usage Medicines (CHMP) has recommended that they do not grant a marketing authorization for Elevidys, rock treatment against Duchenne myopathy for patients aged 3 to 7. HSBC has also reduced the course objective and confirmed “Hold”.
Nestlé (-1.1%) and Novartis (-0.7%) also weighed on the index.
In the aftermath of the semi -annual figures of the Vevey giant, several analysts revised their copy: all have lowered the lecture objective, while the recommendations vary between “Hold” and “Buy”. For Vontobel analyst for example, the group is in a difficult phase. The market seems to lose confidence, because management has trouble convincing investors. For that of Deutsche Bank, it will take time for EBIT figures to reflect what it considers a fundamental improvement in activity.
For Novartis, Bernstein SG lowered the course goal, while confirming “Buy”. The analyst noted his forecast after the solid figures for the second quarter and the raising of the 2025 objectives.
On the expanded market, the Geneva specialist in outside advertising APG SGA (-1.2%) saw his profitability indicators are increasing little in the first half, despite slightly decreasing revenues. He says he is confident for the rest of the exercise.
The BB Biotech Participation Company (-2.0%) dug its losses in the second quarter, allocated mainly by the force of the franc and the volatile markets. She says she is “optimistic” for the second part of the year, despite the risks linked to customs duties, regulation and political discussions on health.
The specialist in the machonic sheet machining (+0.4%) presented red figures in the first half, but still with reduced loss. He expects a market situation always difficult for the rest of the year.
The producer of consumables and equipment supplier of dental cabinets Coltène (-9.3%) saw its net profit more than divided by two over the first six months of the year. The annual objectives are revised downwards.
The active group in the edition, secure printing and the Orell Füssli bookstore (+6.7%) saw its net profit jump in the space of a year to 7.17 million Swiss francs, against 1.83 million twelve months earlier. He noted his objectives in the wake for the whole year.
The producer of composite materials Schweiter (-5.2%) saw his results contract over the first six months of the year, notably affected by exchange rates. He slightly planed his financial prospects for 2025.
The manufacturer of machine tools Starragtornos (-3.7%) suffered net loss in mid-term. It points to the difficult market environment.
The Valiant banking group (+0.5%) managed to improve its half -yearly profit, despite a decrease operating product and increasing charges.
The vontobel management bank (+1.3%) saw its results weaken in the first half in a difficult market context. The assets under management have however progressed in particular with the integration of Ihag.
Zehnder Group (+2.6%) took advantage of the favorable development in the field of ventilation, the Argovian group has significantly progressed in the 1st half.
rp/cw
